The case for & against
Bull & Bear analysis
Strata Skin Sciences, Inc. (NASDAQ: SSKN) is a medical technology company operating within the dermatology sector, specializing in the development and commercialization of innovative dermatological treatment solutions, primarily utilizing its proprietary TheraClear X device and other product offerings. As a company in a turnaround phase, Strata is focused on enhancing device utilization, expanding direct-to-consumer marketing initiatives, and optimizing operational efficiency within partner clinics. The business seeks to capitalize on the growing demand for effective skin condition treatments, leveraging improvements in reimbursement frameworks and expanding market access.
Bull says
- ↑Direct-to-consumer campaigns booked 2,800 new appointments YTD vs 8 in 2023
- ↑CPT code revisions in 2027 could triple addressable patient market
- ↑International revenue jumped 41% YoY to $4.1 million in Q3
- ↑Gross margin expanded to 60.1% for third straight quarterly improvement
- ↑Average revenue per device rose to $5,981, targeting $7,500 long-term
- ↑Dividend yield of 1.21% and strong sensitivity to oil suggest stability
Bear says
- ↓Revenue slipped 1% YoY to $8.8 million in Q3 2024 amid weak demand
- ↓Operating expenses surged to $10 million, driving a $1.6 million net loss
- ↓International revenue declined 15% to $2.6 million due to trade tariffs
- ↓Ongoing litigation risks eight-figure damages and legal expenses
- ↓High customer acquisition costs from DTC could erode future profits
- ↓Negative profitability and high volatility factors underscore value risks
Earnings Call · Q3 2024 · Mgmt. Guidance
Transcript signals
Bull points
- Revenue per extract device grew 2% year over year versus the flat revenue growth seen in the second quarter and versus the decline of 10% seen in fiscal 2023 over fiscal 2022.
- Our gross margin as a percentage of revenue improved for the third consecutive quarter and reached 60.3% in the third quarter versus 56% in the second quarter of 2023.
- Excluding the one-time item, non-GAAP operating expenses decreased to 5.2 million in Q3 of 2024, down from 5.6 million in Q3 of 2023, and down from 5.4 million in the second quarter of 2024.
Bear points
- Our domestic installed base of extract devices decreased slightly from 882 units at the end of the second quarter of this year to 873 units at the end of Q3.
- total revenue for the third quarter of 2024 was 8.8 million versus 8.9 million in the third quarter of 2023, a decline of 1%
- extract gross domestic recurring billings were 4.8 million in the third quarter of 2024, down 2% from 4.9 million in the third quarter of 2023